Researchers at Children’s Hospital of Pittsburgh are testing a vaccine for some children with certain kinds of gliomas. Pediatric Neuro-oncologist, Regina Jakacki, M.D., says the vaccine is made from synthetic versions of three proteins found on the majority of glioma cells. Not everyone has all three, but the majority of glioma patients have at least one of the proteins.

Study participants receive two injections. The first contains the synthetic glioma proteins. The second is a drug, called poly ICLC, which pumps up the immune system. The protocol is repeated every 3 weeks for up to 8 treatments. Those who respond to the vaccine may receive additional vaccinations starting 6 weeks after the last treatment and then once every six weeks for up to two years.

During the trial, participants will provide blood samples every few weeks to check levels of the glioma proteins and immune response to the treatment. Jakacki says participants also receive MRI scans every nine weeks. Studies of the vaccine in adult glioma patients are promising, with some patients surviving longer than expected.

Researchers are hopeful the vaccine treatment will be beneficial for children with glioma as well. Side effects of the vaccine include redness and swelling at the injection site. Jakacki says the treatment may also cause swelling of the tumor inside the brain.

To qualify for the study, patients need to have an HLA-A2 tissue match. Although the study is open to patients across the country, participants must be willing to travel to Pittsburgh to get the injections.

Eligible families who need assistance with travel costs can call (412) 692-7056.

 For information about the trial, go to http://clinicaltrials.gov , then type the trial identification number in the search box: NCT00862199.